Our contributions to EASL 2026 in Barcelona
At a glance
The team contributed to six abstracts at this year's EASL Congress in Barcelona, reflecting ongoing work in hepatology and non-invasive liver-disease risk prediction.
We're excited to announce that our team contributed to six abstracts at this year's EASL Congress in Barcelona, reflecting our ongoing work in hepatology. A special thanks to Dr Rickard Strandberg for his contributions to these projects.
The abstracts at EASL 2026 covered the potential of reflex testing with the CORE model triggered by liver-enzyme abnormalities to improve risk prediction in the general population (SAT-512); changes in non-invasive tests PRO-C3, ADAPT, LiverRisk and FIB-4 to predict changes in liver stiffness in patients with MASLD (WED-104); comparing non-invasive risk scores for predicting adverse liver outcomes in MASLD (WED-057-YI); estimation of liver-fibrosis risk using non-invasive biomarker tests in people living with HIV and prediabetes in Tanzania (SAT-042); external validation and recalibration of the CORE risk score to predict 10-year risk of liver cirrhosis in patients with type 2 diabetes (WED-172-YI); and the time-varying relationship between liver stiffness measurement and all-cause mortality in patients with chronic liver diseases (WED-173).